A detailed history of Quest Partners LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Quest Partners LLC holds 9,431 shares of RCUS stock, worth $137,315. This represents 0.01% of its overall portfolio holdings.

Number of Shares
9,431
Previous 23 40904.35%
Holding current value
$137,315
Previous $350,000 41100.0%
% of portfolio
0.01%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$13.69 - $18.01 $128,795 - $169,438
9,408 Added 40904.35%
9,431 $144 Million
Q2 2024

Aug 06, 2024

BUY
$14.59 - $18.48 $14 - $18
1 Added 4.55%
23 $350,000
Q1 2024

May 09, 2024

SELL
$14.83 - $20.18 $59,186 - $80,538
-3,991 Reduced 99.45%
22 $415,000
Q4 2023

Feb 09, 2024

BUY
$13.43 - $19.63 $53,894 - $78,775
4,013 New
4,013 $76.6 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.05B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Quest Partners LLC Portfolio

Follow Quest Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quest Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quest Partners LLC with notifications on news.